Screen · Berkshire Criteria

Buffett Quality Screen

Buffett's "wonderful business" criteria, quantified into six dimensions: earnings record (20), ROE quality (25 — Fortune's double standard), low leverage (15), pricing power (15), business stability (15) and capital efficiency (10), for a 0–100 total. The entry gate is the first of Berkshire's acquisition criteria — at least $50M average pre-tax earnings over the last three fiscal years (banks and insurers excluded, as leverage is their business model; investment trusts and closed-end funds excluded, as they are portfolios rather than operating companies). Recomputed periodically from each company's last ten fiscal years; cross-listings merged by canonical ticker. Hover the score for the six-dimension breakdown; companies we cover link to their report. score tier "卓越"、market "China A-shares"、market cap "Mid $2–10B"で絞り込み：30 match(絞り込みを解除)。

#	銘柄	Mkt Cap	Score▼	10Y ROE	Profit Streak	Net Debt/Eq	Gross Margin	レポート	FY
1	Shenzhen New Industries Biomedical 300832 · 深圳	$5.3B	93/100 卓越	23.5%low 17.4%	10 yr+	Net cash	75%	—	FY2025
2	Proya Cosmetics Co Ltd Class A 603605 · 上海	$3.3B	93/100 卓越	22.1%low 13.8%	10 yr+	Net cash	66%	—	FY2025
3	Zhejiang Weixing New Building Materials Co Ltd 002372 · 深圳	$2.0B	92/100 卓越	23.9%low 15.2%	10 yr+	Net cash	43%	—	FY2025
4	Jiangsu King's Luck Brewery Joint-Stock Co Ltd 603369 · 上海	$5.0B	91/100 卓越	19.7%low 15.7%	10 yr+	Net cash	74%	—	FY2025
5	Hubei Jumpcan Pharmaceutical Co Ltd 600566 · 上海	$3.4B	91/100 卓越	21.6%low 12.2%	10 yr+	Net cash	83%	—	FY2025
6	Hangzhou Robam Appliances Co Ltd 002508 · 深圳	$2.1B	90/100 卓越	19.8%low 10.9%	10 yr+	Net cash	53%	—	FY2025
7	Yealink Network Technology Corp Ltd 300628 · 深圳	$6.9B	89/100 卓越	28.7%low 20.6%	10 yr+	Net cash	67%	—	FY2025
8	Anhui Gujing Distillery Co Ltd 000596 · 深圳	$7.0B	88/100 卓越	18.6%low 13.9%	10 yr+	Net cash	77%	—	FY2025
9	Anhui Yingjia Distillery Co Ltd 603198 · 上海	$4.4B	87/100 卓越	21.0%low 16.2%	10 yr+	Net cash	66%	—	FY2025
10	HLA GROUP CORP LTD 600398 · 上海	$4.2B	87/100 卓越	19.8%low 11.8%	10 yr+	Net cash	39%	—	FY2025
11	Hebei Yangyuan ZhiHui Beverage Co Ltd 603156 · 上海	$6.8B	86/100 卓越	21.0%low 12.8%	10 yr+	Net cash	48%	—	FY2025
12	Zhejiang Supor Co Ltd 002032 · 深圳	$4.8B	86/100 卓越	28.8%low 23.7%	10 yr+	Net cash	26%	—	FY2025
13	Xiamen Faratronic Co Ltd 600563 · 上海	$4.3B	86/100 卓越	20.2%low 17.3%	10 yr+	Net cash	39%	—	FY2025
14	Livzon Pharmaceutical Group Inc 000513 · 深圳	$3.9B	86/100 卓越	16.0%low 10.2%	10 yr+	Net cash	63%	—	FY2025
15	Shanghai M&G Stationery Inc 603899 · 上海	$3.0B	86/100 卓越	20.8%low 14.1%	10 yr+	Net cash	23%	—	FY2025
16	G-bits Network Technology Xiamen Co Ltd 603444 · 上海	$3.9B	84/100 卓越	28.1%low 19.3%	10 yr+	Net cash	90%	—	FY2025
17	Jiangzhong Pharmaceutical Co Ltd 600750 · 上海	$2.3B	84/100 卓越	15.8%low 12.2%	10 yr+	Net cash	66%	—	FY2025
18	Jafron Biomedical Co Ltd 300529 · 深圳	$2.1B	84/100 卓越	23.3%low 13.9%	10 yr+	Net cash	83%	—	FY2025
19	Huadong Medicine Co Ltd 000963 · 深圳	$7.1B	83/100 卓越	17.6%low 13.5%	10 yr+	Net cash	30%	—	FY2025
20	Lao Feng Xiang Co Ltd A 600612 · 上海	$2.6B	83/100 卓越	18.4%low 11.6%	10 yr+	Net cash	8%	—	FY2025
21	Shandong Himile Mechanical Science & Technology Co Ltd 002595 · 深圳	$8.5B	82/100 卓越	18.1%low 16.2%	10 yr+	Net cash	33%	—	FY2025
22	Chongqing Brewery Co Ltd 600132 · 上海	$3.1B	82/100 卓越	49.8%low 14.7%	10 yr+	Net cash	46%	—	FY2025
23	Dashenlin Pharm Grp Co Ltd 603233 · 上海	$3.0B	82/100 卓越	18.2%low 13.3%	10 yr+	0.0×	38%	—	FY2025
24	Shanghai Friendess Electronics Tech 688188 · 上海	$5.9B	81/100 卓越	27.3%low 11.2%	10 yr+	Net cash	82%	—	FY2025
25	Huali Industrial Group Company Limited 300979 · 深圳	$5.8B	81/100 卓越	30.9%low 19.7%	9 yr	Net cash	23%	—	FY2025
26	Hisense Kelon Electrical Holdings Co Ltd 000921 · 深圳	$5.3B	81/100 卓越	19.1%low 9.4%	10 yr+	Net cash	21%	—	FY2025
27	Shanghai Huace Navigation Technology Ltd 300627 · 深圳	$3.2B	81/100 卓越	17.0%low 12.2%	10 yr+	Net cash	60%	—	FY2025
28	AIMA Technology Group Co Ltd 603529 · 上海	$2.7B	81/100 卓越	25.4%low 13.3%	10 yr+	Net cash	15%	—	FY2025
29	China Resources Sanjiu Medical & Pharmaceutical Co Ltd 000999 · 深圳	$6.0B	80/100 卓越	14.4%low 11.6%	10 yr+	Net cash	60%	—	FY2025
30	Jiangsu Nhwa Pharmaceutical Co Ltd 002262 · 深圳	$3.1B	80/100 卓越	16.2%low 13.1%	10 yr+	Net cash	66%	—	FY2025

Data and methodology: the six dimensions quantify Berkshire's published acquisition criteria and Buffett's shareholder letters (1981/1987/1991/2007 among others). Qualitative tests in the originals (e.g. "simple, understandable business", "management in place") are out of scope, and price ("available at a fair price") is covered by each report's valuation range instead. Financials come from company annual reports (via EODHD); ratios are computed in reporting currency, the USD gate via static FX. "‡" marks companies whose equity is persistently negative or tiny (ROE falls back to ROCE); "†" marks missing gross profit (operating margin used). Investment trusts and closed-end funds are excluded on two tests — name and financial shape (operating margins beyond what an operating company can achieve); REITs and operating asset managers are unaffected. This is a quantitative first pass, not investment advice. When citing this data, please credit Zen Horizon (zh.app). See our methodology for the scoring process.